Symbols / OTLK Stock $0.32 +9.83% Outlook Therapeutics, Inc.
OTLK (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-11 | main | Ascendiant Capital | Buy → Buy | $6 |
| 2026-02-18 | reit | HC Wainwright & Co. | Neutral → Neutral | $1 |
| 2026-02-18 | main | Chardan Capital | Neutral → Neutral | $1 |
| 2026-01-05 | main | Chardan Capital | Neutral → Neutral | $1 |
| 2026-01-02 | main | HC Wainwright & Co. | Neutral → Neutral | $1 |
| 2025-12-22 | main | Ascendiant Capital | Buy → Buy | $10 |
| 2025-09-30 | reit | HC Wainwright & Co. | Neutral → Neutral | $1 |
| 2025-09-22 | main | Ascendiant Capital | Buy → Buy | $8 |
| 2025-08-29 | down | Guggenheim | Buy → Neutral | — |
| 2025-08-29 | down | HC Wainwright & Co. | Buy → Neutral | $1 |
| 2025-08-28 | main | Chardan Capital | Neutral → Neutral | $3 |
| 2025-08-15 | main | Chardan Capital | Neutral → Neutral | $3 |
| 2025-06-06 | main | Ascendiant Capital | Buy → Buy | $21 |
| 2025-02-24 | main | Ascendiant Capital | Buy → Buy | $24 |
| 2025-02-18 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-02-18 | main | Chardan Capital | Neutral → Neutral | $3 |
| 2025-01-17 | reit | Guggenheim | Buy → Buy | $12 |
| 2025-01-17 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-12-02 | down | Chardan Capital | Buy → Neutral | — |
| 2024-11-29 | main | BTIG | Buy → Buy | $9 |
- $0.31 a share: Outlook closes $5M financing with new warrants - Stock Titan hu, 23 Apr 2026 20
- OTLK | Outlook Therapeutics, Inc. Common Insider Trading - Quiver Quantitative Sun, 19 Apr 2026 18
- OTLK Stock Crashes 67% in a Week: Here's What You Need to Know - Yahoo Finance Wed, 07 Jan 2026 08
- Outlook Therapeutics (OTLK) Announces $5M Share Offering - GuruFocus Wed, 22 Apr 2026 15
- Outlook sells 16.1M shares at 31 cents to raise $5M in direct sale - Stock Titan Wed, 22 Apr 2026 12
- Intel stock soars on Q1 earnings beat, strong outlook - Yahoo Finance Fri, 24 Apr 2026 20
- Outlook Therapeutics Grants Stock Options to New Employees as Part of Inducement Package | OTLK Stock News - Quiver Quantitative Fri, 26 Dec 2025 08
- FDA accepts Outlook dispute request, sets April eye-drug meeting - Stock Titan ue, 07 Apr 2026 07
- UAL Outlook Hits Stock: Buy ETF or Stay Cautious on Fuel Risks? - Yahoo Finance hu, 23 Apr 2026 16
- Outlook Therapeutics (OTLK) joint holders report 4.99% stake after SPA - Stock Titan Fri, 24 Apr 2026 21
- [8-K] Outlook Therapeutics, Inc. Reports Material Event - Stock Titan hu, 23 Apr 2026 20
- Outlook Therapeutics sells 20M shares, closes $5M financing - Stock Titan Wed, 25 Mar 2026 07
- Outlook Therapeutics (NASDAQ: OTLK) raises $5M via 16.13M-share deal - Stock Titan hu, 23 Apr 2026 11
- After an FDA dispute meeting, Outlook awaits May feedback on eye drug - Stock Titan ue, 21 Apr 2026 13
- OTLK SEC Filings - Outlook Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan hu, 02 Apr 2026 02
Insider Transactions
Financials
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Total Revenue |
|
1.41
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
1.41
|
0.00
|
0.00
|
0.00
|
| Cost Of Revenue |
|
1.36
|
0.00
|
—
|
—
|
| Reconciled Cost Of Revenue |
|
1.36
|
0.00
|
—
|
—
|
| Gross Profit |
|
0.06
|
0.00
|
—
|
—
|
| Operating Expense |
|
67.12
-6.39%
|
71.70
+34.97%
|
53.13
-15.77%
|
63.07
|
| Research And Development |
|
27.18
-34.92%
|
41.76
+57.88%
|
26.45
-37.51%
|
42.33
|
| Selling General And Administration |
|
39.94
+33.39%
|
29.94
+12.25%
|
26.67
+28.61%
|
20.74
|
| General And Administrative Expense |
|
39.94
+33.39%
|
29.94
+12.25%
|
26.67
+28.61%
|
20.74
|
| Salaries And Wages |
|
16.66
+53.03%
|
10.89
+21.94%
|
8.93
-2.14%
|
9.12
|
| Other Gand A |
|
23.28
+22.18%
|
19.05
+7.37%
|
17.75
+52.76%
|
11.62
|
| Total Expenses |
|
68.48
-4.50%
|
71.70
+34.97%
|
53.13
-15.77%
|
63.07
|
| Operating Income |
|
-67.06
+6.47%
|
-71.70
-34.97%
|
-53.13
+15.77%
|
-63.07
|
| Total Operating Income As Reported |
|
-67.06
+6.47%
|
-71.70
-34.97%
|
-53.13
+15.77%
|
-63.07
|
| EBITDA |
|
-63.58
+11.81%
|
-72.09
-27.81%
|
-56.40
+12.36%
|
-64.36
|
| Normalized EBITDA |
|
-106.59
+3.74%
|
-110.73
-98.17%
|
-55.88
+12.41%
|
-63.80
|
| Reconciled Depreciation |
|
0.12
+2.80%
|
0.11
+157.67%
|
0.04
-78.41%
|
0.20
|
| EBIT |
|
-63.69
+11.79%
|
-72.21
-27.92%
|
-56.45
+12.57%
|
-64.56
|
| Total Unusual Items |
|
43.02
+11.33%
|
38.64
+7435.32%
|
-0.53
+5.88%
|
-0.56
|
| Total Unusual Items Excluding Goodwill |
|
43.02
+11.33%
|
38.64
+7435.32%
|
-0.53
+5.88%
|
-0.56
|
| Special Income Charges |
|
—
|
0.00
+100.00%
|
-0.58
+43.67%
|
-1.03
|
| Other Special Charges |
|
—
|
—
|
0.58
-43.67%
|
1.03
|
| Impairment Of Capital Assets |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-62.42
+17.17%
|
-75.37
-27.78%
|
-58.98
+10.70%
|
-66.05
|
| Pretax Income |
|
-63.98
+15.11%
|
-75.36
-27.78%
|
-58.98
+10.70%
|
-66.05
|
| Net Non Operating Interest Income Expense |
|
-0.19
+91.41%
|
-2.25
-44.31%
|
-1.56
-4.86%
|
-1.49
|
| Interest Expense Non Operating |
|
0.28
-91.03%
|
3.16
+24.72%
|
2.53
+70.17%
|
1.49
|
| Net Interest Income |
|
-0.19
+91.41%
|
-2.25
-44.31%
|
-1.56
-4.86%
|
-1.49
|
| Interest Expense |
|
0.28
-91.03%
|
3.16
+24.72%
|
2.53
+70.17%
|
1.49
|
| Interest Income Non Operating |
|
0.09
-90.10%
|
0.91
-6.72%
|
0.97
|
—
|
| Interest Income |
|
0.09
-90.10%
|
0.91
-6.72%
|
0.97
|
—
|
| Other Income Expense |
|
3.28
+332.53%
|
-1.41
+67.16%
|
-4.29
-187.93%
|
-1.49
|
| Other Non Operating Income Expenses |
|
-39.60
+0.88%
|
-39.95
-963.56%
|
-3.76
-325.41%
|
-0.88
|
| Gain On Sale Of Security |
|
43.02
+11.33%
|
38.64
+75781.38%
|
0.05
-89.07%
|
0.47
|
| Tax Provision |
|
-1.55
-55522.46%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
1.03
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-62.42
+17.17%
|
-75.37
-27.78%
|
-58.98
+10.70%
|
-66.05
|
| Net Income From Continuing Operation Net Minority Interest |
|
-62.42
+17.17%
|
-75.37
-27.78%
|
-58.98
+10.70%
|
-66.05
|
| Net Income From Continuing And Discontinued Operation |
|
-62.42
+17.17%
|
-75.37
-27.78%
|
-58.98
+10.70%
|
-66.05
|
| Net Income Continuous Operations |
|
-62.42
+17.17%
|
-75.37
-27.78%
|
-58.98
+10.70%
|
-66.05
|
| Normalized Income |
|
-104.41
+8.42%
|
-114.00
-95.03%
|
-58.46
+10.74%
|
-65.49
|
| Net Income Common Stockholders |
|
-62.42
+17.17%
|
-75.37
-27.78%
|
-58.98
+10.70%
|
-66.05
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
—
|
—
|
| Diluted EPS |
|
-1.79
+55.91%
|
-4.06
+15.42%
|
-4.80
+22.58%
|
-6.20
|
| Basic EPS |
|
-1.79
+55.91%
|
-4.06
+15.42%
|
-4.80
+22.58%
|
-6.20
|
| Basic Average Shares |
|
34.80
+87.59%
|
18.55
+48.29%
|
12.51
+17.96%
|
10.60
|
| Diluted Average Shares |
|
34.80
+87.59%
|
18.55
+48.29%
|
12.51
+17.96%
|
10.60
|
| Diluted NI Availto Com Stockholders |
|
-62.42
+17.17%
|
-75.37
-27.78%
|
-58.98
+10.70%
|
-66.05
|
| Earnings From Equity Interest |
|
-0.14
-39.97%
|
-0.10
-816.00%
|
-0.01
+77.43%
|
-0.05
|
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Total Assets |
|
18.58
-35.52%
|
28.82
-10.77%
|
32.30
+13.23%
|
28.53
|
| Current Assets |
|
17.39
-36.57%
|
27.42
-11.50%
|
30.98
+12.57%
|
27.52
|
| Cash Cash Equivalents And Short Term Investments |
|
8.08
-45.85%
|
14.93
-36.19%
|
23.39
+34.46%
|
17.40
|
| Cash And Cash Equivalents |
|
8.08
-45.85%
|
14.93
-36.19%
|
23.39
+34.46%
|
17.40
|
| Receivables |
|
1.49
|
0.00
|
—
|
—
|
| Accounts Receivable |
|
1.49
|
0.00
|
—
|
—
|
| Inventory |
|
3.34
|
0.00
|
—
|
—
|
| Raw Materials |
|
2.35
|
—
|
—
|
—
|
| Work In Process |
|
0.96
|
—
|
—
|
—
|
| Finished Goods |
|
0.03
|
—
|
—
|
—
|
| Prepaid Assets |
|
—
|
—
|
—
|
10.12
|
| Other Current Assets |
|
4.48
-64.15%
|
12.49
+64.60%
|
7.59
-25.05%
|
10.12
|
| Total Non Current Assets |
|
1.20
-15.06%
|
1.41
+6.49%
|
1.32
+31.18%
|
1.01
|
| Net PPE |
|
0.23
-17.89%
|
0.27
+949.38%
|
0.03
-62.80%
|
0.07
|
| Gross PPE |
|
0.23
-17.89%
|
0.27
+949.38%
|
0.03
-62.80%
|
0.07
|
| Accumulated Depreciation |
|
—
|
—
|
—
|
-1.07
|
| Other Properties |
|
0.23
-17.89%
|
0.27
+949.38%
|
0.03
-62.80%
|
0.07
|
| Investments And Advances |
|
0.55
-20.34%
|
0.69
-12.69%
|
0.79
-1.37%
|
0.80
|
| Long Term Equity Investment |
|
0.55
-20.34%
|
0.69
-12.69%
|
0.79
-1.37%
|
0.80
|
| Other Non Current Assets |
|
0.42
-4.95%
|
0.44
-12.37%
|
0.50
+279.73%
|
0.13
|
| Total Liabilities Net Minority Interest |
|
50.77
-50.17%
|
101.90
+118.02%
|
46.74
+136.16%
|
19.79
|
| Current Liabilities |
|
45.81
+7.66%
|
42.55
-8.94%
|
46.73
+136.86%
|
19.73
|
| Payables And Accrued Expenses |
|
12.78
+6.07%
|
12.05
+17.48%
|
10.26
+50.84%
|
6.80
|
| Payables |
|
10.49
+6.81%
|
9.83
+16.54%
|
8.43
+57.65%
|
5.35
|
| Accounts Payable |
|
10.19
+27.90%
|
7.97
+21.21%
|
6.57
+88.30%
|
3.49
|
| Current Accrued Expenses |
|
2.29
+2.78%
|
2.22
+21.84%
|
1.83
+25.77%
|
1.45
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
3.03
+198.91%
|
1.01
+10.11%
|
0.92
-53.45%
|
1.98
|
| Total Tax Payable |
|
0.30
-83.73%
|
1.86
+0.00%
|
1.86
+0.00%
|
1.86
|
| Income Tax Payable |
|
0.30
-83.73%
|
1.86
+0.00%
|
1.86
+0.00%
|
1.86
|
| Current Debt And Capital Lease Obligation |
|
30.01
+1.75%
|
29.49
-17.06%
|
35.56
+224.59%
|
10.95
|
| Current Debt |
|
29.95
+1.72%
|
29.44
-17.19%
|
35.55
+225.71%
|
10.92
|
| Other Current Borrowings |
|
29.95
+1.72%
|
29.44
-17.19%
|
35.55
+225.71%
|
10.92
|
| Current Capital Lease Obligation |
|
0.06
+15.70%
|
0.05
+1093.04%
|
0.00
-88.99%
|
0.04
|
| Total Non Current Liabilities Net Minority Interest |
|
4.96
-91.65%
|
59.35
+954168.13%
|
0.01
-89.87%
|
0.06
|
| Long Term Debt And Capital Lease Obligation |
|
0.19
-23.54%
|
0.25
|
0.00
-100.00%
|
0.00
|
| Long Term Debt |
|
—
|
—
|
—
|
—
|
| Long Term Capital Lease Obligation |
|
0.19
-23.54%
|
0.25
|
0.00
-100.00%
|
0.00
|
| Stockholders Equity |
|
-32.19
+55.95%
|
-73.08
-406.15%
|
-14.44
-265.26%
|
8.74
|
| Common Stock Equity |
|
-32.19
+55.95%
|
-73.08
-406.15%
|
-14.44
-265.26%
|
8.74
|
| Capital Stock |
|
0.54
+125.42%
|
0.24
+83.71%
|
0.13
-94.28%
|
2.27
|
| Common Stock |
|
0.54
+125.42%
|
0.24
+83.71%
|
0.13
-94.28%
|
2.27
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
53.89
+125.42%
|
23.91
+83.71%
|
13.01
+14.49%
|
11.37
|
| Ordinary Shares Number |
|
53.89
+125.42%
|
23.91
+83.71%
|
13.01
+14.49%
|
11.37
|
| Additional Paid In Capital |
|
572.98
+21.92%
|
469.97
+3.67%
|
453.35
+9.14%
|
415.40
|
| Retained Earnings |
|
-605.71
-11.49%
|
-543.28
-16.11%
|
-467.92
-14.42%
|
-408.94
|
| Total Equity Gross Minority Interest |
|
-32.19
+55.95%
|
-73.08
-406.15%
|
-14.44
-265.26%
|
8.74
|
| Total Capitalization |
|
-32.19
+55.95%
|
-73.08
-406.15%
|
-14.44
-265.26%
|
8.74
|
| Working Capital |
|
-28.43
-87.78%
|
-15.14
+3.91%
|
-15.75
-302.20%
|
7.79
|
| Invested Capital |
|
-2.24
+94.87%
|
-43.64
-306.68%
|
21.11
+7.44%
|
19.65
|
| Total Debt |
|
30.19
+1.54%
|
29.74
-16.36%
|
35.56
+224.47%
|
10.96
|
| Net Debt |
|
21.86
+50.66%
|
14.51
+19.36%
|
12.16
|
—
|
| Capital Lease Obligations |
|
0.25
-16.83%
|
0.30
+6879.82%
|
0.00
-90.08%
|
0.04
|
| Net Tangible Assets |
|
-32.19
+55.95%
|
-73.08
-406.15%
|
-14.44
-265.26%
|
8.74
|
| Tangible Book Value |
|
-32.19
+55.95%
|
-73.08
-406.15%
|
-14.44
-265.26%
|
8.74
|
| Current Notes Payable |
|
—
|
—
|
—
|
—
|
| Derivative Product Liabilities |
|
4.77
-91.93%
|
59.10
+950197.68%
|
0.01
-89.12%
|
0.06
|
| Interest Payable |
|
—
|
—
|
—
|
0.00
|
| Investments In Other Ventures Under Equity Method |
|
—
|
—
|
—
|
—
|
| Investmentsin Joint Venturesat Cost |
|
0.55
-20.34%
|
0.69
-12.69%
|
0.79
-1.37%
|
0.80
|
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-51.83
+24.66%
|
-68.79
-60.08%
|
-42.97
+24.18%
|
-56.67
|
| Cash Flow From Continuing Operating Activities |
|
-51.83
+24.66%
|
-68.79
-60.08%
|
-42.97
+24.18%
|
-56.67
|
| Net Income From Continuing Operations |
|
-62.42
+17.17%
|
-75.37
-27.78%
|
-58.98
+10.70%
|
-66.05
|
| Depreciation Amortization Depletion |
|
0.12
+2.80%
|
0.11
+157.67%
|
0.04
-78.41%
|
0.20
|
| Depreciation And Amortization |
|
0.12
+2.80%
|
0.11
+157.67%
|
0.04
-78.41%
|
0.20
|
| Other Non Cash Items |
|
33.52
+1149.95%
|
2.68
+95.58%
|
1.37
-17.16%
|
1.66
|
| Stock Based Compensation |
|
8.90
+65.23%
|
5.39
-2.92%
|
5.55
-28.06%
|
7.71
|
| Asset Impairment Charge |
|
—
|
—
|
—
|
—
|
| Operating Gains Losses |
|
-42.87
-3993.89%
|
-1.05
-294.76%
|
0.54
-11.61%
|
0.61
|
| Gain Loss On Investment Securities |
|
-43.02
-3646.93%
|
-1.15
-2154.62%
|
-0.05
+89.07%
|
-0.47
|
| Unrealized Gain Loss On Investment Securities |
|
6.07
+147.22%
|
2.46
-34.58%
|
3.76
+325.41%
|
0.88
|
| Change In Working Capital |
|
4.86
+261.00%
|
-3.02
-163.49%
|
4.75
+382.19%
|
-1.68
|
| Change In Receivables |
|
-1.49
|
0.00
|
—
|
—
|
| Changes In Account Receivables |
|
-1.49
|
0.00
|
—
|
—
|
| Change In Inventory |
|
-3.34
|
0.00
|
—
|
—
|
| Change In Prepaid Assets |
|
8.01
+263.47%
|
-4.90
-287.29%
|
2.62
+184.61%
|
-3.09
|
| Change In Payables And Accrued Expense |
|
1.82
-3.41%
|
1.89
-20.47%
|
2.37
+63.40%
|
1.45
|
| Change In Accrued Expense |
|
1.71
+247.79%
|
0.49
+169.10%
|
-0.71
-555.78%
|
0.16
|
| Change In Payable |
|
0.11
-92.01%
|
1.39
-54.78%
|
3.08
+138.05%
|
1.30
|
| Change In Account Payable |
|
1.67
+19.50%
|
1.39
-54.78%
|
3.08
+138.05%
|
1.30
|
| Change In Other Current Assets |
|
-0.10
-1514.36%
|
-0.01
+97.17%
|
-0.21
|
0.00
|
| Change In Other Current Liabilities |
|
-0.05
-1568.83%
|
0.00
+112.64%
|
-0.03
+37.01%
|
-0.04
|
| Investing Cash Flow |
|
—
|
—
|
—
|
—
|
| Cash Flow From Continuing Investing Activities |
|
—
|
—
|
—
|
—
|
| Net Business Purchase And Sale |
|
—
|
—
|
—
|
—
|
| Purchase Of Business |
|
—
|
—
|
—
|
—
|
| Financing Cash Flow |
|
44.98
-25.43%
|
60.33
+23.20%
|
48.97
-17.83%
|
59.59
|
| Cash Flow From Continuing Financing Activities |
|
44.98
-25.43%
|
60.33
+23.20%
|
48.97
-17.83%
|
59.59
|
| Net Issuance Payments Of Debt |
|
-3.04
-71205.04%
|
-0.00
-100.02%
|
19.77
+952.41%
|
-2.32
|
| Issuance Of Debt |
|
33.10
|
0.00
-100.00%
|
30.00
+200.00%
|
10.00
|
| Repayment Of Debt |
|
-36.14
-846925.69%
|
-0.00
+99.96%
|
-10.23
+16.94%
|
-12.32
|
| Long Term Debt Issuance |
|
33.10
|
0.00
-100.00%
|
30.00
+200.00%
|
10.00
|
| Long Term Debt Payments |
|
-36.14
-846925.69%
|
-0.00
+99.96%
|
-10.23
+16.94%
|
-12.32
|
| Net Long Term Debt Issuance |
|
-3.04
-71205.04%
|
-0.00
-100.02%
|
19.77
+952.41%
|
-2.32
|
| Net Common Stock Issuance |
|
25.40
-57.91%
|
60.33
+100.95%
|
30.02
-51.81%
|
62.31
|
| Proceeds From Stock Option Exercised |
|
22.63
|
0.00
|
0.00
-100.00%
|
0.21
|
| Net Other Financing Charges |
|
—
|
—
|
-0.82
-37.32%
|
-0.60
|
| Changes In Cash |
|
-6.84
+19.14%
|
-8.46
-241.19%
|
6.00
+105.35%
|
2.92
|
| Beginning Cash Position |
|
14.93
-36.19%
|
23.39
+34.46%
|
17.40
+20.17%
|
14.48
|
| End Cash Position |
|
8.08
-45.85%
|
14.93
-36.19%
|
23.39
+34.46%
|
17.40
|
| Free Cash Flow |
|
-51.83
+24.66%
|
-68.79
-60.08%
|
-42.97
+24.18%
|
-56.67
|
| Interest Paid Supplemental Data |
|
0.00
-100.00%
|
0.47
-59.05%
|
1.16
-25.48%
|
1.56
|
| Change In Income Tax Payable |
|
-1.55
|
0.00
|
—
|
—
|
| Change In Tax Payable |
|
-1.55
|
0.00
|
—
|
—
|
| Common Stock Issuance |
|
25.40
-57.91%
|
60.33
+100.95%
|
30.02
-51.81%
|
62.31
|
| Earnings Losses From Equity Investments |
|
0.14
+39.97%
|
0.10
+816.00%
|
0.01
-77.43%
|
0.05
|
| Issuance Of Capital Stock |
|
25.40
-57.91%
|
60.33
+100.95%
|
30.02
-51.81%
|
62.31
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-23 View
- 8-K2026-04-21 View
- 8-K2026-04-07 View
- 8-K2026-03-25 View
- 8-K2026-03-16 View
- 8-K2026-03-11 View
- 8-K2026-03-10 View
- 8-K2026-03-05 View
- 8-K2026-02-18 View
- 10-Q2026-02-17 View
- 8-K2026-02-17 View
- 8-K2026-02-11 View
- 8-K2026-01-02 View
- 10-K2025-12-19 View
- 8-K2025-12-19 View
- 8-K2025-11-13 View
- 8-K2025-11-03 View
- 42025-10-03 View
- 42025-10-03 View
- 42025-10-03 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|